In this issue:
ASCT in older adults with MM
Levofloxacin prophylaxis reduces infections and death in NDMM
KEYNOTE-183 shows no benefit to the addition of pembrolizumab to standard therapy in RRMM
Clinical outcomes not improved with pembrolizumab in NDMM in KEYNOTE-185 trial
Outcomes of patients with MM refractory to CD38-targeted mAb therapy
Dual CAR-T cell combination therapy shows promise for RRMM
Nelfinavir for rescue of lenalidomide-refractory MM
PomDex with additional cyclophosphamide for RRMM in Asia
Single nucleotide polymorphisms of the CRMB gene predict AEs to thalidomide
Synergistic plasma cell death is achieved using a combination of HDAC and MEK or BCL-2 inhibitor
Please login below to download this issue (PDF)